Structural and Functional Grey and White Matter Changes in Patients With Pain Disorders

January 16, 2025 updated by: University Hospital, Basel, Switzerland
The goal of this observational study is to examine the association between exact lesion location and presence of thalamic CPSP (Central post-stroke pain) in a larger number of patients after thalamic stroke.

Study Overview

Detailed Description

The researchers will explore how the brain areas and mechanisms of brain plasticity are involved in the generation of thalamic CPSP, compared to other pain disorders, using structural and functional magnetic resonance imaging (MRI) at 3 Tesla. The functional magnetic resonance imaging (fMRI) will be also used to assess the cerebral processing of heat/cold stimuli in patients with thalamic pain compared to thalamic stroke patients without pain, to patients with migraine (other central pain disorder) and to normal controls. In addition the researchers want to assess the somatosensory profile of thalamic pain patients and compare it with thalamic stroke patients without pain, patients with migraine (pain control) and normal controls.

Study Type

Observational

Enrollment (Actual)

82

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Basel, Switzerland, 4031
        • University Hospital Basel, Department of Neurology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The recruitment of patients with thalamic pain will take place at the Department of Neurology, University Hospital Basel in collaboration with the chronic pain service of the Department of Anesthesiology, University Hospital Basel and the "Schmerzklinik Kirschgarten" in Basel. The recruitment of patients with thalamic stroke without pain as well as of patients with migraine (other pain disorder) will take place at the Department of Neurology, University Hospital Basel, the latter especially from the "Kopfsprechstunde". Healthy subjects will be recruited by public announcements on the University Hospital's and the University's notice board and website.

Description

Inclusion Criteria:

  1. Patients with thalamic central post-stroke pain (CPSP) :

    Patients fulfilling all of the following inclusion criteria are eligible for the study:

    • Informed Consent as documented by signature (Appendix Informed Consent Form)
    • History of thalamic stroke (infarction or bleed)
    • Diagnosis of definite central-post stroke pain (according to the criteria proposed by Klit et al, 2009)
    • No other chronic pain condition
    • Age: ≥18 years old
  2. Patients with thalamic stroke without CPSP:

    Patients fulfilling all of the following inclusion criteria are eligible for the study:

    • Informed Consent as documented by signature (Appendix Informed Consent Form)
    • History of thalamic stroke (infarction or bleed), at least 2 years ago
    • No chronic pain condition (neither CPSP or other pain condition)
    • Age ≥18 years old
  3. Patients with migraine (other pain condition):

    Patients fulfilling all of the following inclusion criteria are eligible for the study:

    • Informed Consent as documented by signature (Appendix Informed Consent Form)
    • History of highly frequent (≥8 monthly migraine days) or chronic migraine (≥15 monthly migraine days).
    • No history of stroke
    • Age ≥18 years old
  4. Healthy controls:

Participants fulfilling all of the following inclusion criteria are eligible for the study:

  • Informed Consent as documented by signature (Appendix Informed Consent Form)
  • No history of stroke
  • No chronic pain condition
  • Age: ≥18 years old

Exclusion Criteria:

  • History of severe neurological, internistic or psychiatric disease
  • MRI related exclusion criteria:

    • paramagnetic and/or superparamagnetic foreign objects in the body (especially when located close to the brain)
    • Pacemaker
    • Claustrophobia
    • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with thalamic CPSP (central post-stroke pain)
Patients with CPSP of thalamic origin due to stroke.

The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.

  1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations
  2. Thermal pain threshold
  3. Mechanical detection thresholds for touch
  4. Mechanical pain threshold for pinprick stimuli
  5. Stimulus-response functions
  6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus
  7. Vibration detection threshold
  8. Pressure pain threshold

Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.

For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.

A "painful heat/cold stimulation" will be performed to study the differences in pain processing between the three groups

The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.

Structured telephone interview with 3 Questionnaires

  1. The german pain questionnaire
  2. Questionnaire regarding clinical development since the last visit designed by the investigators
  3. German translation of 12-item-allodynia symptom checklist (ASC-12)
Patients with thalamic stroke without CPSP
Patients with thalamic stroke at least 2 years ago, but without CPSP or other chronic pain disorders

The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.

  1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations
  2. Thermal pain threshold
  3. Mechanical detection thresholds for touch
  4. Mechanical pain threshold for pinprick stimuli
  5. Stimulus-response functions
  6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus
  7. Vibration detection threshold
  8. Pressure pain threshold

Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.

For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.

A "painful heat/cold stimulation" will be performed to study the differences in pain processing between the three groups

The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.

Structured telephone interview with 3 Questionnaires

  1. The german pain questionnaire
  2. Questionnaire regarding clinical development since the last visit designed by the investigators
  3. German translation of 12-item-allodynia symptom checklist (ASC-12)
Patients with migraine
Patients with migraine (other central pain disorder)

The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.

  1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations
  2. Thermal pain threshold
  3. Mechanical detection thresholds for touch
  4. Mechanical pain threshold for pinprick stimuli
  5. Stimulus-response functions
  6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus
  7. Vibration detection threshold
  8. Pressure pain threshold

Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.

For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.

A "painful heat/cold stimulation" will be performed to study the differences in pain processing between the three groups

The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.
Healthy controls
Age- and gender-matched healthy control subjects

The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.

  1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations
  2. Thermal pain threshold
  3. Mechanical detection thresholds for touch
  4. Mechanical pain threshold for pinprick stimuli
  5. Stimulus-response functions
  6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus
  7. Vibration detection threshold
  8. Pressure pain threshold

Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.

For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.

A "painful heat/cold stimulation" will be performed to study the differences in pain processing between the three groups

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The exact lesion location in the thalamus in patients with thalamic pain compared to patients with thalamic stroke without pain
Time Frame: One time assessment with a duration of max. 90 minutes.
To determine the mutual lesion location in patients with CPSP of thalamic origin in standard stereotactic space using high-resolution 3 T MRI data and to calculate odds ratio maps for the risk of developing CPSP of thalamic origin with lesion of specific areas of the thalamus.
One time assessment with a duration of max. 90 minutes.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Structural gray matter changes in patients with thalamic pain compared to the other patient groups and the healthy controls
Time Frame: One time assessment with a duration of max. 90 minutes.
The 3 dimensional MPRAGE images will be used to assess cortical thickness and subcortical morphometry
One time assessment with a duration of max. 90 minutes.
Structural white matter changes in patients with thalamic pain compared to the other patient groups and the healthy controls
Time Frame: One time assessment with a duration of max. 90 minutes.
Diffusion Tensor Imaging (DTI) will be used to asess the integrity of the white matter
One time assessment with a duration of max. 90 minutes.
Functional brain changes regarding the connectivity of pain networks in patients with thalamic pain compared to the other patient groups and the healthy controls
Time Frame: One time assessment with a duration of max. 90 minutes.
Resting state fMRI (functional MRI) will be used to assess the functional connectivity between the thalamus and cortical areas next to the default-mode network and the sensory-motor network.
One time assessment with a duration of max. 90 minutes.
Functional brain changes regarding the central processing of heat/cold stimulation in patients with thalamic pain compared to the other patient groups and the healthy controls
Time Frame: One time assessment with a duration of max. 90 minutes.
Painful heat- and cold stimulation will be performed during the fMRI session at one time-point to assess the central processing of pain in all participants
One time assessment with a duration of max. 90 minutes.
Somatosensory profile of patients with thalamic pain vs. migraine (pain-control-group)
Time Frame: One time assessment with a duration of max. 60 minutes.
Somatosensory profile will be assessed by quantitative sensory testing (QST). This standardized, internationally accepted test battery consists of well-established, non-invasive tests, which are performed on the face, hand or foot of the participants. The tests measure parameters which reflect nearly all aspects of somatosensation (thermal detection thresholds, thermal pain thresholds, mechanical detection thresholds for touch, mechanical pain threshold, mechanical allodynia, vibration detection threshold and pressure pain threshold).
One time assessment with a duration of max. 60 minutes.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of severity and characteristics of pain.
Time Frame: Two time assessment at baseline and 8-year-follow-up with a duration of max. 60 minutes.
Pain characteristics will be assessed by the German pain questionnaire ("Deutscher Schmerzfragebogen"). It is a detailed questionnaire for the standardized collection of relevant pain characteristics, which is commonly used in the German language area. The first 8 items (sensory adjectives) represent a qualitative sensory description of pain that can provide information for the differential diagnosis of individual pain syndromes (e.g. headache, neuropathic pain). A summary evaluation is carried out for the affective scale. For this purpose, the total value (0-12) is formed from the individual ratings (each from 0 to 3) of the last four items (affective adjectives: miserable, horrid, horrible, terrible). A total value of 8 (corresponds to a percentage of 75%) can be set as the limit value for an increased affective experience of pain; values above this are to be assessed as conspicuous.
Two time assessment at baseline and 8-year-follow-up with a duration of max. 60 minutes.
Longitudinal evaluation of clinical development in CPSP
Time Frame: One time assessment with a duration of max. 10 minutes.
The clinical development of CPSP will be assessed by an 8-year follow-up interview via phone call. The interview/questionnaire consists of 6 questions.
One time assessment with a duration of max. 10 minutes.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Athina Papadopoulou, PD Dr. med., University Hospital Basel, Department of Neurology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 4, 2015

Primary Completion (Actual)

December 27, 2024

Study Completion (Actual)

December 27, 2024

Study Registration Dates

First Submitted

December 21, 2022

First Submitted That Met QC Criteria

January 9, 2023

First Posted (Actual)

January 10, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 16, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-00028; ko22Papadopoulou

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Central Post-stroke Pain

Clinical Trials on Quantitative sensory testing (QST)

Subscribe